A PHASE 1 DOSE ESCALATION STUDY OF GCC19CART – A NOVEL COUPLEDCAR® THERAPY FOR SUBJECTS WITH METASTATIC COLORECTAL CANCER

Naifei Chen, Chengfei Pu, Lingling Zhao, Ning Li, Chang Wang, Yusheng Huang, Susa Luo, Yun Li, Zhenzhou Yang, Jun Bie, Ruihong Zhu, Yi Huang, Haiyang Tang, Tingting Liang, Yizhuo Wang, Beibei Jia, Dongqi Chen, Victor Lu, Zhao Wu, Tingting Liang, Lei Xiao, Jiuwei Cui.

1 The First Bethune Hospital of Jilin University, Changchun, China; 2 Innovative Cellular Therapeutics, Shanghai, China; 3 Zhengzhou University, Zhengzhou, China; 4 The Second Affiliated Hospital of CQMU, Chongqing, China; 5 Henan Cancer Hospital, Zhengzhou, China; 6 The First Hospital of Lanzhou University, Lanzhou, China; 7 Chongqing Medical University, Shanghai, China; 8 Nanchong Central Hospital, Nanchong, China; 9 Innovative Cellular Therapeutics, Inc., Rockville, MD, USA; 10 Henan Cancer Hospital, Zhengzhou, China; 11 The First Hospital of Jilin University, Changchun, China

Background GCC19CART, the first clinical candidate from the CoupledCAR® solid tumor platform, targets guanylate cyclase-C (GCC) which is expressed in colorectal cancers. CoupledCAR utilizes multiple vectors to make both solid tumor targeting CAR-T and CD19 CAR-T in a single manufacturing step. An investigator-initiated dose escalation trial in China for patients with relapsed or refractory metastatic colorectal cancer (R/R mCRC) is reported here.

Methods Subjects are screened for GCC expression by immunohistochemistry. Eligible subjects undergo leukapheresis, a single dose of lymphodepleting chemotherapy (fludarabine 30mg/m^2 and cyclophosphamide 300mg/m^2) 3 days prior to infusion, and then administration of a single infusion of GCC19CART at one of two preassigned doses: 1x10^6 or 2x10^6 CAR T-cells/kg. Endpoints are safety and preliminary evidence of efficacy as determined by CT or PET/CT per RECIST 1.1 or PERCIST 1.0. All responses were confirmed by an independent third-party imaging contract research organization (CRO).

Results 13 subjects have been enrolled to dose level 1 (1x10^6 cells/kg) and 8 subjects have been enrolled to dose level 2 (2x10^6 cells/kg). The most common adverse events were cytokine release syndrome (CRS) in 21/21 subjects (Grade 1 19/21 (90.48%) or Grade 2 2/21 (9.52%) and diarrhea in 21/21 subjects (Grade 1 6/21 (28.57%) Grade 2 5/21 (23.81%) Grade 3 9/21 (42.86%) or Grade 4 1/21 (4.76%). All patients with grade 3 and higher side effects were well managed. Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in 2/21 (9.52%) subjects at Grade 3 or 4 resolved with corticosteroids. The combined overall response rate (ORR) for both dose levels was 28.6% (6/21). For dose level 1, the overall response rate (ORR) per RECIST 1.1 was 15.4% (2/13). Two subjects demonstrated a partial response (PR) while 3 additional subjects had partial metabolic response (PMR) on PET/CT with stable disease (SD) or progressive disease (PD) per RECIST 1.1. For dose level 2, The ORR per RECIST 1.1 was 50% (4/8). 4 subjects demonstrated a PR (3 at month 1, 1 at month 3 after being SD at month 1) and 2 additional subjects had PMR on PET/CT with SD per RECIST 1.1.

Conclusions Preliminary results demonstrate that GCC19CART has meaningful dose-dependent clinical activity and an acceptable safety profile in relapsed or refractory metastatic colorectal cancer. This trial is ongoing and updated data will be presented. A Phase 1 trial of GCC19CART in the US has opened for accrual and is expected to enroll patients in mid-2022.

http://dx.doi.org/10.1136/jitc-2023-SITC2023.0644